Panelists discuss how thrombotic risk assessment—anchored in age, thrombotic history, and additional factors like leukocytosis and JAK2 allele burden—guides personalized therapy in polycythemia vera (PV), balancing cytoreduction, symptom control, and prevention of vascular events.
Summary for Physicians: Thrombotic Risk Assessment in PV and Its Role in Guiding Therapy
Thrombotic risk assessment is a critical component of therapeutic decision-making in polycythemia vera (PV), as thrombotic events are a leading cause of morbidity and mortality in this disease. Risk stratification is primarily based on clinical factors, but additional markers can further inform treatment strategy.
Key Elements of Risk Assessment:
Impact on Treatment Strategy:
The approach emphasizes balancing thrombotic risk reduction with disease control and quality of life, using a tailored strategy based on individual patient characteristics.